Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Antibodies 2012, 1(1), 88-123; doi:10.3390/antib1010088

Natural Killer (NK)- and T-Cell Engaging Antibody-Derived Therapeutics

, 2,†,*  and 2
Received: 19 April 2012; in revised form: 21 May 2012 / Accepted: 24 May 2012 / Published: 1 June 2012
(This article belongs to the Special Issue Modes of Antibody Action for Cancer Therapy)
View Full-Text   |   Download PDF [518 KB, uploaded 1 June 2012]   |   Browse Figures
Abstract: Unmodified antibodies (abs) have been successful in the treatment of hematologic malignancies, but less so for the treatment of solid tumors. They trigger anti-tumor effects through their Fc-domains, and one way to improve their efficacy is to optimize their interaction with the effectors through Fc-engineering. Another way to empower abs is the design of bispecific abs and related fusion proteins allowing a narrower choice of effector cells. Here we review frequently chosen classes of effector cells, as well as common trigger molecules. Natural Killer (NK)- and T-cells are the most investigated populations in therapeutical approaches with bispecific agents until now. Catumaxomab, the first bispecific ab to receive drug approval, targets the tumor antigen Epithelial Cell Adhesion Molecule (EpCAM) and recruits T-cells via a binding site for the cell surface protein CD3. The next generation of recombinant ab-derivatives replaces the broadly reactive Fc-domain by a binding domain for a single selected trigger. Blinatumomab is the first clinically successful member of this class, targeting cancer cells via CD19 and engaging T-cells by CD3. Other investigators have developed related recombinant fusion proteins to recruit effectors, such as NK-cells and macrophages. The first such agents currently in preclinical and clinical development will be discussed.
Keywords: NK-cell; T-cell; effector cell; tumor therapy; Fc receptor; bispecific antibody NK-cell; T-cell; effector cell; tumor therapy; Fc receptor; bispecific antibody
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |

MDPI and ACS Style

Stein, C.; Schubert, I.; Fey, G.H. Natural Killer (NK)- and T-Cell Engaging Antibody-Derived Therapeutics. Antibodies 2012, 1, 88-123.

AMA Style

Stein C, Schubert I, Fey GH. Natural Killer (NK)- and T-Cell Engaging Antibody-Derived Therapeutics. Antibodies. 2012; 1(1):88-123.

Chicago/Turabian Style

Stein, Christoph; Schubert, Ingo; Fey, Georg H. 2012. "Natural Killer (NK)- and T-Cell Engaging Antibody-Derived Therapeutics." Antibodies 1, no. 1: 88-123.

Antibodies EISSN 2073-4468 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert